TY - JOUR
T1 - Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity
AU - Gudmundsdotter, Lindvi
AU - Nilsson, Charlotta
AU - Brave, Andreas
AU - Hejdeman, Bo
AU - Earl, Patricia
AU - Moss, Bernard
AU - Robb, Merlin
AU - Cox, Josephine
AU - Michael, Nelson
AU - Marovich, Mary
AU - Biberfeld, Gunnel
AU - Sandström, Eric
AU - Wahren, Britta
N1 - Funding Information:
This study was supported by the European Union (INCO-DEV A4 ICFP501A4PR03, AVIP 503487); Swedish International Development Cooperation Agency (Sida); Department of Research Cooperation (SAREC) (SWE-2004-120, HIV2004-000809, 2004:813); Swedish Research Council (Vetenskapsrådet, K2004-16x-07743-19); Läkare mot AIDS Forskningsfond (04-050301 and 01-051101). Construction of the HIV-1 modified vaccinia virus Ankara was supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health and the US Military HIV Research Program. The production costs were funded by the US Military HIV Research Program, Walter Reed Army Institute of Research.
PY - 2009/7/16
Y1 - 2009/7/16
N2 - The presence of vector-specific immune responses may hamper the induction of responses to a foreign antigen encoded by the vector. We evaluated the impact of pre-existing immunity to vaccinia virus on the induction of HIV-specific responses after immunization of healthy volunteers with a HIV-1 DNA prime-MVA boost vaccine. Following three priming immunizations with HIV-1 DNA plasmids, the volunteers were boosted with a single injection of recombinant MVA encoding HIV-1 proteins. Pre-existing immunity to vaccinia virus did not reduce the proportion of individuals who responded to HIV-1, but did lower the magnitude of responses. Our results suggest that vaccinia-based vectors can be used to efficiently induce immune responses to vectored HIV-1 antigens, even in individuals with pre-existing immunity to vaccinia virus.
AB - The presence of vector-specific immune responses may hamper the induction of responses to a foreign antigen encoded by the vector. We evaluated the impact of pre-existing immunity to vaccinia virus on the induction of HIV-specific responses after immunization of healthy volunteers with a HIV-1 DNA prime-MVA boost vaccine. Following three priming immunizations with HIV-1 DNA plasmids, the volunteers were boosted with a single injection of recombinant MVA encoding HIV-1 proteins. Pre-existing immunity to vaccinia virus did not reduce the proportion of individuals who responded to HIV-1, but did lower the magnitude of responses. Our results suggest that vaccinia-based vectors can be used to efficiently induce immune responses to vectored HIV-1 antigens, even in individuals with pre-existing immunity to vaccinia virus.
KW - HIV-1 vaccine
KW - Modified Vaccinia virus Ankara (MVA)
KW - Pre-existing immunity
UR - http://www.scopus.com/inward/record.url?scp=67649338409&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2009.05.018
DO - 10.1016/j.vaccine.2009.05.018
M3 - Article
C2 - 19450644
AN - SCOPUS:67649338409
SN - 0264-410X
VL - 27
SP - 4468
EP - 4474
JO - Vaccine
JF - Vaccine
IS - 33
ER -